|
|
| (31 intermediate revisions by 9 users not shown) |
| Line 1: |
Line 1: |
| {{Infobox_Disease | | __NOTOC__ |
| | Name = Myasthenia gravis
| | {| class="infobox" style="float:right;" |
| | Width = 230
| | |- |
| | DiseasesDB = 8460
| | | [[File:Siren.gif|30px|link=Myasthenia gravis resident survival guide]]|| <br> || <br> |
| | ICD10 = {{ICD10|G|70|0|g|70}}
| | | [[Myasthenia gravis resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] |
| | ICD9 = {{ICD9|358.0}}
| | |} |
| | ICDO =
| | '''For patient information click [[Myasthenia gravis (patient information)|here]].''' |
| | OMIM = 254200
| |
| | MedlinePlus = 000712
| |
| | MeshID = D009157
| |
| }}
| |
| {{CMG}}
| |
| | |
| {{Myasthenia gravis}} | | {{Myasthenia gravis}} |
| | {{CMG}}; {{AE}} {{Fs}} |
|
| |
|
| | {{SK}} |
|
| |
|
| | ==[[Myasthenia gravis overview|Overview]]== |
|
| |
|
| | ==[[Myasthenia gravis historical perspective|Historical Perspective]]== |
|
| |
|
| ==Signs and symptoms== | | ==[[Myasthenia gravis classification|Classification]]== |
| The hallmark of myasthenia gravis is [[muscle weakness]] that increases during periods of activity and improves after periods of rest. Muscles that control eye and eyelid movement, facial expression, [[chewing]], [[Manner of articulation|talking]], and [[swallowing]] are especially susceptible. The muscles that control [[breath]]ing and neck and limb movements can also be affected. Often the physical examination is within normal limits.<ref name="Scherer">{{cite journal | author=Scherer K, Bedlack RS, Simel DL. | title=Does this patient have myasthenia gravis? | journal=[[JAMA]] | year=2005 | volume=293 | issue=15 | pages=1906–14 | pmid=15840866 | doi=10.1001/jama.293.15.1906}}</ref>
| |
| | |
| The onset of the disorder can be sudden or rapid. Often symptoms come and go over time. The diagnosis of myasthenia gravis may be delayed if the symptoms are subtle or variable.
| |
| | |
| In most cases, the first noticeable symptom is weakness of the eye muscles. In others, difficulty in swallowing and slurred speech may be the first signs. The degree of muscle weakness involved in MG varies greatly among patients, ranging from a localized form, limited to eye muscles ([[ocular myasthenia]]), to a severe or generalized form in which many muscles - sometimes including those that control breathing - are affected. Symptoms, which vary in type and severity, may include asymmetrical [[ptosis (eyelid)|ptosis]] (a drooping of one or both [[eyelid]]s), [[diplopia]] (double vision) due to weakness of the muscles that control eye movements, unstable or waddling gait, weakness in arms, hands, fingers, legs, and neck, a change in facial expression, [[dysphagia]] (difficulty in swallowing), shortness of breath and [[dysarthria]] (impaired speech, often nasal due to weakness of the pharyngeal muscles).
| |
| | |
| In ''myasthenic crisis'' a [[paralysis]] of the respiratory muscles occurs, necessitating [[assisted ventilation]] to sustain life. In patients whose respiratory muscles are already weak, crises may be triggered by infection, fever, an adverse reaction to medication, or emotional stress.<ref>{{cite journal | author=Bedlack RS, Sanders DB. | title=How to handle myasthenic crisis. Essential steps in patient care. | journal=Postgrad Med | year=2000 | volume=107 | issue=4 | pages=211–4, 220-2 | url=http://www.postgradmed.com/issues/2000/04_00/bedlack.htm | pmid=10778421}}</ref> Since the [[cardiac muscle|heart muscle]] is stimulated differently, it is never affected by MG.
| |
|
| |
|
| ==Pathophysiology== | | ==[[Myasthenia gravis pathophysiology|Pathophysiology]]== |
| Myasthenia gravis is an [[autoimmune disease]]: it features antibodies directed against the body's own proteins. While in various similar diseases the disease has been linked to a cross-reaction with an infective agent, there is no known causative [[pathogen]] that could account for myasthenia. There is a slight genetic predisposition: particular [[Human leukocyte antigen|HLA]] types seem to predispose for MG (B8 and DR3 with DR1 more specific for ocular myasthenia). Up to 75% of patients have an abnormality of the thymus; 25% have a [[thymoma]], a tumor (either benign or malignant) of the [[thymus]], and other abnormalities are frequently found. The disease process generally remains stationary after thymectomy (removal of the thymus). | |
|
| |
|
| In MG, the autoantibodies are directed most commonly against the [[acetylcholine receptor]] ([[nicotinic acetylcholine receptor|nicotinic type]]), the [[receptor (biochemistry)|receptor]] in the [[motor end plate]] for the [[neurotransmitter]] [[acetylcholine]] that stimulates muscular contraction. Some forms of the antibody impair the ability of acetylcholine to bind to receptors. Others lead to the destruction of receptors, either by [[complement system|complement]] fixation or by inducing the muscle cell to eliminate the receptors through [[endocytosis]].
| | ==[[Myasthenia gravis causes|Causes]]== |
|
| |
|
| The antibodies are produced by plasma cells, that have been derived from B cells. These plasma cells are activated by T-helper cells, which in turn are activated by binding to acetylcholine receptor antigenic peptide sequences (epitopes) that rest within the histocompatibility antigens of antigen presenting cells. The thymus plays an important role in the development of T-cells, which is why myasthenia gravis is associated with thymoma. The exact mechanisms are however not convincingly clarified.
| | ==[[Differentiating Myasthenia gravis from other diseases|Differentiating Myasthenia Gravis from other Diseases]]== |
|
| |
|
| In normal [[muscle contraction]], cumulative activation of the ACh receptor leads to influx of [[sodium]] and [[calcium]]. Only when the levels of these electrolytes inside the muscle cell is high enough will it contract. Decreased numbers of functioning receptors therefore impairs muscular contraction.
| | ==[[Myasthenia gravis epidemiology and demographics|Epidemiology and Demographics]]== |
|
| |
|
| It has recently been realized that a second category of gravis is due to auto-antibodies against the [[MuSK protein]] (muscle specific kinase), a [[tyrosine kinase]] receptor which is required for the formation of the [[neuromuscular junction]]. Antibodies against MuSK inhibit the signaling of MuSK normally induced by its nerve-derived ligand, [[agrin]]. The result is a decrease in patency of the neuromuscular junction, and the consequent symptoms of MG.
| | ==[[Myasthenia gravis risk factors|Risk Factors]]== |
|
| |
|
| People treated with penicillamine can develop MG symptoms. Their antibody titer is usually similar to that of MG, but both the symptoms and the titer disappear when drug administration is discontinued.
| | ==[[Myasthenia gravis screening|Screening]]== |
|
| |
|
| MG is more common in families with other autoimmune diseases. A familial predisposition is found in 5% of the cases. This is associated with certain genetic variations such as an increased frequency of HLA-B8 and DR3. People with MG suffer from co-existing autoimmune diseases at a higher frequency than members of the general population. Of particular mention is co-existing [[thyroid disease]] where episodes of [[hypothyroidism]] may precipitate a severe exacerbation.
| | ==[[Myasthenia gravis natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
|
| |
|
| ==Diagnosis== | | ==Diagnosis== |
| Myasthenia can be a difficult diagnosis, as the symptoms can be subtle and hard to distinguish from both normal variants and other neurological disorders.<ref name="Scherer">{{cite journal | author=Scherer K, Bedlack RS, Simel DL. | title=Does this patient have myasthenia gravis? | journal=[[JAMA]] | year=2005 | volume=293 | pages=1906–14 | id=PMID 15840866}}</ref> A thorough [[physical examination]] can reveal easy fatiguability, with the weakness improving after rest and worsening again on repeat of the exertion testing. Applying ice to weak muscle groups characteristically leads to improvement in strength of those muscles. Additional tests are often performed, as mentioned below. Furthermore, a good response to medication can also be considered a sign of autoimmune pathology. | | [[Myasthenia gravis history and symptoms|History and Symptoms]] | [[Myasthenia gravis physical examination|Physical Examination]] | [[Myasthenia gravis laboratory findings|Laboratory Findings]] | [[Myasthenia gravis electrocardiogram|Electrocardiogram]] |[[Myasthenia gravis chest x ray|Chest X Ray]] | [[Myasthenia gravis CT|CT]] | [[Myasthenia gravis MRI|MRI]] | [[Myasthenia gravis echocardiography or ultrasound| Echocardiography or Ultrasound]] | [[Myasthenia gravis other imaging findings|Other Imaging Findings]] | [[Myasthenia gravis other diagnostic studies|Other Diagnostic Studies]] |
| | |
| ===Physical examination===
| |
| Muscle fatigability can be tested for many muscles. A thorough investigation includes:
| |
| * looking upward and sidewards for 30 seconds: [[ptosis (eyelid)|ptosis]] and [[diplopia]].
| |
| * looking at the feet while lying on the back for 60 seconds
| |
| * keeping the arms stretched forward for 60 seconds
| |
| * 10 deep knee bends
| |
| * walking 30 steps on both the toes and the heels
| |
| * 5 situps, lying down and sitting up completely
| |
| | |
| ===Blood tests===
| |
| If the diagnosis is suspected, [[serology]] can be performed in a [[blood test]] to identify [[antibody|antibodies]] against the [[acetylcholine receptor]]. The test has a reasonable [[Sensitivity (tests)|sensitivity]] of 80–96%, but in MG limited to the eye muscles (ocular myasthenia) the test may be negative in up to 50% of the cases. About half of the patients without antibodies against the acetylcholine receptor have antibodies against the [[MuSK protein]]. In specific situations (decreased reflexes which increase on facilitation, co-existing autonomic features, suspected presence of neoplasm, presence of increment or facilitation on repetitive EMG testing) testing is performed for [[Lambert-Eaton syndrome]], in which other antibodies (against a voltage-gated [[calcium channel]]) can be found.
| |
| | |
| ===Neurophysiology===
| |
| Muscle fibers of patients with MG are easily fatigued, and thus do not respond as well as muscles in healthy individuals to repeated stimulation. By repeatedly stimulating a muscle with electrical impulses, the fatiguability of the muscle can be measured. This is called the repetitive nerve stimulation test. In single fiber [[electromyography]], which is considered to be the most sensitive (although not the most specific) test for MG, a thin needle electrode is inserted into a muscle to record the electric potentials of individual muscle fibers. By finding two muscle fibers belonging to the same motor unit and measuring the temporal variability in their firing patterns (i.e. their 'jitter'), the diagnosis can be made.
| |
| | |
| ===Edrophonium test===
| |
| The "edrophonium test" is infrequently performed to identify MG; its application is limited to the situation when other investigations do not yield a conclusive diagnosis. This test requires the [[intravenous]] administration of [[edrophonium|edrophonium chloride]] (Tensilon®, Reversol®), a drug that blocks the breakdown of acetylcholine by [[cholinesterase]] and temporarily increases the levels of acetylcholine at the [[neuromuscular junction]]. In people with myasthenia gravis involving the eye muscles, edrophonium chloride will briefly relieve weakness.
| |
| | |
| ===Imaging===
| |
| A [[chest X-ray]] is frequently performed; it may point towards alternative diagnoses (e.g. Lambert-Eaton due to a lung tumor) and comorbidity. It may also identify widening of the [[mediastinum]] suggestive of [[thymoma]], but [[computed tomography]] (CT) or [[magnetic resonance imaging]] (MRI) are more sensitive ways to identify thymomas, and are generally done for this reason.
| |
| | |
| ===Pulmonary function test===
| |
| [[Spirometry]] (lung function testing) may be performed to assess respiratory function if there are concerns about a patient's ability to breathe adequately. The vital capacity (VC) may be monitored at intervals in order not to miss a gradual worsening of muscular weakness. Severe myasthenia may cause [[respiratory failure]] due to exhaustion of the respiratory muscles. | |
| | |
| ===Pathological findings===
| |
| [[Immunofluorescence]] shows [[IgG]] antibodies on the neuromuscular junction. (Note that it is not the antibody which causes myasthenia gravis that fluoresces, but rather a [[secondary antibody]] directed against it.) Muscle electron microscopy shows receptor infolding and loss of the tips of the folds, together with widening of the [[Chemical synapse|synaptic]] clefts. Both these techniques are currently used for research rather than diagnostically.
| |
| | |
| ==Classification==
| |
| The most widely accepted classification of myasthenia gravis is the Myasthenia Gravis Foundation of America Clinical Classification:<ref name="pmid10891897">{{cite journal |author=Jaretzki A, Barohn RJ, Ernstoff RM, ''et al'' |title=Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America |journal=Neurology |volume=55 |issue=1 |pages=16–23 |year=2000 |pmid=10891897 |url=http://www.neurology.org/cgi/content/full/55/1/16}}</ref>
| |
| * Class I: Any eye muscle weakness, possible ptosis, no other evidence of muscle weakness elsewhere
| |
| * Class II: Eye muscle weakness of any severity, mild weakness of other muscles
| |
| ** Class IIa: Predominantly limb or axial muscles
| |
| ** Class IIb: Predominantly bulbar and/or respiratory muscles
| |
| * Class III: Eye muscle weakness of any severity Moderate weakness of other muscles
| |
| ** Class IIIa: Predominantly limb or axial muscles
| |
| ** Class IIIb: Predominantly bulbar and/or respiratory muscles
| |
| * Class IV: Eye muscle weakness of any severity, severe weakness of other muscles
| |
| ** Class IVa: Predominantly limb or axial muscles
| |
| ** Class IVb: Predominantly bulbar and/or respiratory muscles (Can also include feeding tube without intubation)
| |
| * Class V: Intubation needed to maintain airway
| |
| | |
| ==Associations==
| |
| Myasthenia Gravis is associated with various [[autoimmune]] diseases, including:
| |
| * [[Thyroid]] diseases, including [[Hashimoto's thyroiditis]] and [[Graves' disease]]
| |
| * [[Diabetes mellitus type 1]]
| |
| * [[Rheumatoid arthritis]]
| |
| * [[Systemic lupus erythematosus|Lupus]], and
| |
| * [[Demyelinating disease|Demyelinating CNS diseases]]
| |
| | |
| Seropositive and "double-seronegative" patients often have [[thymoma]] or thymic hyperplasia. However, anti-MuSK positive patients do not have evidence of thymus pathology.
| |
|
| |
|
| ==Treatment== | | ==Treatment== |
| Treatment is by medication and/or surgery. Medication consists mainly of [[cholinesterase inhibitors]] to directly improve muscle function and [[immunosuppressant drug]]s to reduce the autoimmune process. [[Thymectomy]] is a surgical method to treat MG. For emergency treatment, [[plasmapheresis]] or [[IVIG]] can be used as a temporary measure to remove antibodies from the blood circulation.
| | [[Myasthenia gravis medical therapy|Medical Therapy]] | [[Myasthenia gravis surgery|Surgery]] | [[Myasthenia gravis primary prevention|Primary Prevention]] | [[Myasthenia gravis secondary prevention|Secondary Prevention]] | [[Myasthenia gravis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Myasthenia gravis future or investigational therapies|Future or Investigational Therapies]] |
| | |
| ===Medication===
| |
| | |
| * [[Cholinesterase inhibitors]]: [[neostigmine]] and [[pyridostigmine]] can improve muscle function by slowing the natural enzyme [[cholinesterase]] that degrades [[acetylcholine]] in the motor end plate; the neurotransmitter is therefore around longer to stimulate its receptor. Usually doctors will start with a low dose, eg 3x20mg pyridostigmine, and increase until the desired result is achieved. If taken 30 minutes before a meal, symptoms will be mild during eating. Side effects, like perspiration and diarrhea can be countered by adding [[atropine]]. Pyridostigmine is a short-lived drug with a half-life of about 4 hours.
| |
| | |
| * [[Immunosuppressive drugs]]: [[prednisone]], [[cyclosporine]], [[mycophenolate mofetil]] and [[azathioprine]] may be used. It is common for patients to be treated with a combination of these drugs with a cholinesterase inhibitor. Treatments with some immunosuppressives take weeks to months before effects are noticed.
| |
| | |
| ===Plasmapheresis and IVIG===
| |
| If the myasthenia is serious (myasthenic crisis), [[plasmapheresis]] is used to remove the putative antibody from the circulation. Similarly, [[intravenous immunoglobulin]]s (IVIG) are used to bind the circulating antibodies. Both of these treatments have relatively short-lived benefits, typically measured in weeks.
| |
| | |
| ===Surgery===
| |
| {{main|thymectomy}}
| |
| | |
| Thymectomy, the surgical removal of the [[thymus]], is essential in cases of [[thymoma]] in view of the potential neoplastic effects of the tumor. However, the procedure is more controversial in patients who do not show thymic abnormalities. Although some of these patients improve following thymectomy, some patients experience severe exacerbations and the highly controversial concept of "therapeutic thymectomy" for patients with thymus hyperplasia is disputed by many experts and efforts are underway to unequivocally answer this important question.
| |
| | |
| There are a number of surgical approaches to the removal of the thymus gland: transsternal (through the [[sternum]], or breast bone), transcervical (through a small neck incision), and transthoracic (through one or both sides of the chest). The transsternal approach is most common and uses the same length-wise incision through the sternum (breast bone)used for most open-heart surgery. The transcervical approach is a less invasive procedure that allows for removal of the entire thymus gland through a small neck incision. There has been no difference in success in symptom improvement between the transsternal approach and the minimally invasive transcervical approach.<ref name=Calhoun_1999>{{cite journal |author=Calhoun R, et al. |title=Results of transcervical thymectomy for myasthenia gravis in 100 consecutive patients. |journal=Annals of Surgery |volume=230 |issue=4 |pages=555-561 |year=1999 |pmid=10522725}}</ref>
| |
| | |
| Thymoma is relatively rare in younger (<40) patients, but paradoxically especially younger patients with generalized MG without thymoma benefit from thymectomy. Of course, resection is also indicated for those with a thymoma, but it is less likely to improve the MG symptoms.
| |
| | |
| ==Prognosis==
| |
| With treatment, patients have a normal life expectancy, except for those with a malignant [[thymoma]] (whose lesser life expectancy is on account of the thymoma itself and is otherwise unrelated to the myasthenia). Quality of life can vary depending on the severity and the cause. The drugs used to control MG either diminish in effectiveness over time ([[cholinesterase|cholinesterase inhibitors]]) or cause severe side effects of their own ([[Immunosupressive drug|immunosupressants]]). A small percentage (around 10%) of MG patients are found to have tumors in their [[thymus]] glands, in which case a [[thymectomy]] is a very effective treatment with long-term remission. However, most patients need treatment for the remainder of their lives, and their abilities vary greatly. It should be noted that MG is not usually a progressive disease. The symptoms may come and go, but the symptoms usually do not get worse as the patient ages. For some, the symptoms decrease after a span of 3–5 years.
| |
| | |
| ==Epidemiology==
| |
| Myasthenia gravis occurs in all ethnic groups and both genders. It most commonly affects women under 40 - and people from 50 to 70 years old of either sex, but it has been known to occur at any age. Younger patients rarely have thymoma. The prevalence in the [[United States]] is estimated at 20 cases per 100,000 in the United States.<ref name="MGFA">{{cite web | title=What is Myasthenia Gravis (MG)? | url=http://www.myasthenia.org/amg_whatismg.cfm | publisher=Myasthenia Gravis Foundation of America}}</ref> Risk factors are the female gender with ages 20 – 40, familial myasthenia gravis, D-penicillamine ingestion (drug induced myasthenia), and having other autoimmune diseases. | |
| | |
| Three types of myasthenia symptoms in children can be distinguished:
| |
| # Neonatal: In 12% of the pregnancies with a mother with MG, she passes the antibodies to the infant through the [[placenta]] causing neonatal myasthenia gravis. The symptoms will start in the first two days and disappear within a few weeks after birth. With the mother it is not uncommon for the symptoms to even improve during pregnancy, but they might worsen after labor.
| |
| # Congenital: Children of a healthy mother can, very rarely, develop myasthenic symptoms beginning at birth. This is called [[Congenital Myasthenic Syndrome]] or CMS. Other than Myasthenia gravis, CMS is not caused by an autoimmune process, but due to synaptic malformation, which in turn is caused by genetic [[mutations]]. Thus, CMS is a [[hereditary disease]]. More than 11 different mutations have been identified and the inheritance pattern is typically [[recessive gene|autosomal recessive]].
| |
| # Juvenile myasthenia gravis: myasthenia occurring in childhood but after the peripartum period.
| |
| | |
| The congenital myasthenias cause muscle weakness and fatigability similar to those of MG. The symptoms of CMS usually begin within the first two years of life, although in a few forms patients can develop their first symptoms as late as the seventh decade of life. A diagnosis of CMS is suggested by the following:
| |
| * Onset of symptoms in infancy or childhood.
| |
| * Weakness which increases as muscles tire.
| |
| * A decremental EMG response, on low frequency, of the compound muscle action potential (CMAP).
| |
| * No anti-AChR or MuSK antibodies.
| |
| * No response to immunosuppressant therapy.
| |
| * Family history of symptoms which resemble CMS.
| |
| | |
| The symptoms of CMS can vary from mild to severe. It is also common for patients with the same form, even members of the same family, to be affected to differing degrees. In most forms of CMS weakness does not progress, and in some forms, the symptoms may diminish as the patient gets older. Only rarely do symptoms of CMS become worse with time.
| |
| | |
| | |
| | |
| ==References==
| |
| <!-- ----------------------------------------------------------
| |
| See http://en.wikipedia.org/wiki/Wikipedia:Footnotes for a
| |
| discussion of different citation methods and how to generate
| |
| footnotes using the <ref>, </ref> and <reference /> tags
| |
| ----------------------------------------------------------- -->
| |
| <div class="references-2column"><references/></div>
| |
| | |
| ==External links==
| |
| * [http://www.myasthenia.org The Myasthenia Gravis Foundation of America]
| |
| * [http://www.mgauk.org The Myasthenia Gravis Association (MGA) in the United Kingdom & the Republic of Ireland]
| |
| | |
| {{PNS diseases of the nervous system}}
| |
|
| |
|
| [[Category:Autoimmune diseases]]
| | ==Case Studies== |
| [[Category:Neurology]] | | [[Myasthenia gravis case study one|Case #1]] |
|
| |
|
| | [[Category:Rheumatology]] |
| | [[Category:Help]] |
| | [[Category:Needs content]] |
|
| |
|
| {{WH}} | | {{WH}} |
| {{WS}} | | {{WS}} |
